PREVACID IV Drug Patent Profile

When do Prevacid Iv patents expire, and when can generic versions of Prevacid Iv launch?

Prevacid Iv is a drug marketed by Takeda Pharms Na and is included in one NDA.

The generic ingredient in PREVACID IV is lansoprazole. There are fifty-six drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the lansoprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prevacid Iv

A generic version of PREVACID IV was approved as lansoprazole by MYLAN PHARMS INC on November 10^th, 2009.

Summary for PREVACID IV

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	137
Clinical Trials:	42
Patent Applications:	4,887
DailyMed Link:	PREVACID IV at DailyMed

Recent Clinical Trials for PREVACID IV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Research & Development, LLC	Phase 1
McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4
McGill University Health Center	Phase 4

See all PREVACID IV clinical trials

US Patents and Regulatory Information for PREVACID IV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004		DISCN	Yes	No

Expired US Patents for PREVACID IV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004	4,628,098*PED
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004	7,396,841*PED

International Patents for PREVACID IV

See the table below for patents covering PREVACID IV around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4136340
Ireland	851976
Hong Kong	4792	PYRIDINE DERIVATIVES AND THEIR PRODUCTION
Canada	2419067	COMPOSITION INJECTABLE COMRENANT UN COMPOSE DE BENZIMIDAZOLEET UN ALKALI FORT (INJECTABLE COMPOSITION COMPRISING BENZIMIDAZOLE COMPOUND ANDSTRONG ALKALI)

Supplementary Protection Certificates for PREVACID IV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210
1129088	2014/008	Ireland		PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209

Prevacid IV: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Prevacid IV (lansoprazole for injection) is a proton pump inhibitor (PPI) used to treat gastrointestinal conditions. Its market performance is influenced by patent exclusivity, generic competition, clinical demand, and pricing strategies. The U.S. market for intravenous PPIs is characterized by a limited number of therapeutic options and established treatment protocols.

What is the U.S. Patent Landscape for Prevacid IV?

The principal patent for lansoprazole, the active pharmaceutical ingredient in Prevacid IV, expired years ago, paving the way for generic entry. However, secondary patents covering specific formulations, manufacturing processes, or methods of use can extend market exclusivity.

• Compound Patent Expiration: U.S. Patent 4,628,098, covering lansoprazole itself, expired in November 2005. This marked the initial point of significant generic competition for oral lansoprazole products [1].
• Formulation Patents: Patents related to specific formulations of lansoprazole, particularly those suitable for intravenous administration, may have had later expiration dates. For Prevacid IV, the focus would be on patents that provided a competitive advantage or extended market protection beyond the compound patent.
• Regulatory Exclusivity: Prevacid IV, as a branded pharmaceutical, also benefited from U.S. Food and Drug Administration (FDA) regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity if it was developed as a novel formulation or indication. However, these also have finite terms [2].
• Generic Entry Impact: The expiration of key patents and the subsequent entry of generic lansoprazole for injection products have significantly altered the market dynamics, leading to price erosion and a shift in market share towards lower-cost alternatives.

What are the Current Market Dynamics for Intravenous Proton Pump Inhibitors in the U.S.?

The U.S. market for intravenous PPIs is largely driven by hospital settings for patients unable to take oral medications due to severe gastrointestinal bleeding, stress ulcer prophylaxis in intensive care units, or other acute conditions.

• Key Indications:
  • Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
  • Short-term treatment of active duodenal ulcers.
  • Short-term treatment of active gastric ulcers.
  • Maintenance of healing of erosive esophagitis and reduction of gastric acid secretion.
  • Stress ulcer prophylaxis in critically ill patients [3].
• Competitive Set: The intravenous PPI market includes other approved agents like pantoprazole sodium for injection. The choice between agents is often influenced by physician preference, hospital formularies, cost, and perceived efficacy in specific clinical scenarios.
• Pricing Trends: Branded intravenous PPIs historically commanded premium pricing. However, the introduction of generics has led to substantial price reductions. This trend is exacerbated by hospital purchasing power and the emphasis on cost containment.
• Market Size and Growth: While precise market size figures for the intravenous segment are less readily available than for oral PPIs, the overall PPI market in the U.S. is substantial. The growth of the intravenous segment is tied to the prevalence of conditions requiring its use and the availability of effective intravenous treatments. The market for IV PPIs is likely mature, with growth influenced by demographic shifts and advancements in patient care protocols rather than significant therapeutic innovation in this specific delivery method.
• Prescribing Patterns: Prescriptions for IV PPIs are concentrated in hospital inpatient settings, particularly in intensive care units (ICUs) and during surgical recovery. Outpatient use is minimal due to the availability of oral formulations and the invasiveness of IV administration.

What is the Historical Financial Performance of Prevacid IV?

The financial trajectory of Prevacid IV is closely linked to its patent exclusivity period and the subsequent impact of generic competition.

• Peak Sales Period: During its period of market exclusivity, Prevacid IV, as part of the broader Prevacid franchise, generated significant revenue for its originator. Specific sales data for the intravenous formulation are often aggregated with oral formulations in public financial reporting. However, the launch of the injectable form offered a distinct revenue stream targeting acute care settings.
• Impact of Generic Entry: Following the loss of patent exclusivity for lansoprazole, the introduction of generic versions of lansoprazole for injection led to a sharp decline in Prevacid IV's market share and average selling price (ASP). This is a standard pattern for branded pharmaceuticals once patent protection is lost.
• Current Revenue Contribution: The current revenue generated by Prevacid IV is substantially lower than its peak. It competes with generic alternatives on price and availability. Its financial contribution is now primarily from a reduced number of prescriptions where brand preference or specific contractual agreements might still favor the originator product.
• Sales Reporting: Takeda Pharmaceuticals, the originator, historically reported significant sales for its lansoprazole products. Post-genericization, the revenue attributable to the branded Prevacid IV would be a fraction of its historical peak. Detailed segment reporting for the IV formulation versus oral formulations is not consistently disclosed after generic entry.

How has Generic Competition Affected Prevacid IV's Market Share and Pricing?

Generic competition has fundamentally reshaped the market for Prevacid IV.

• Market Share Erosion: Since the advent of generic lansoprazole for injection, the market share of branded Prevacid IV has diminished significantly. Generic products typically capture the majority of the market due to their lower cost, especially within hospital procurement systems that prioritize cost-effectiveness.
• Price Reductions: The introduction of generics forces a significant reduction in the ASP of the branded product to remain competitive, although it often remains priced at a premium. The price differential between branded Prevacid IV and its generic counterparts is substantial, often exceeding 70-80% [4].
• Negotiated Contracts: Hospitals and large healthcare systems often negotiate volume-based pricing for both branded and generic drugs. While Prevacid IV might retain some market share through these contracts, the overall pricing environment is downward-biased due to generic availability.
• Formulation Specifics: The market for injectable drugs can sometimes exhibit slower generic penetration than oral drugs due to manufacturing complexities, smaller market volumes, and established physician and pharmacy protocols. However, for established generics like lansoprazole, this effect is typically limited.

What are the Future Outlook and Potential Opportunities for Prevacid IV?

The future outlook for Prevacid IV is largely defined by its position as a mature, post-patent product facing intense generic competition.

• Limited Innovation Potential: As a branded product that has lost its primary patent protection, significant investment in novel research and development for Prevacid IV itself is unlikely. Focus would shift to lifecycle management strategies if applicable.
• Niche Market Persistence: Prevacid IV may continue to serve a niche within hospitals and acute care settings. Prescribing decisions will increasingly hinge on cost-effectiveness, formulary status, and specific patient profiles where prior clinical experience with the brand might still be a factor.
• Competition from Other PPIs and H2 Blockers: Intravenous formulations of other PPIs, such as pantoprazole, and even intravenous histamine-2 receptor antagonists (H2 blockers), may present alternative treatment options, further fragmenting the market.
• Potential for Continued Sales Through Established Channels: The established supply chain and physician familiarity with Prevacid IV could ensure a baseline level of sales. However, this will be capped by the aggressive pricing of generics.
• No Significant Growth Prospects: Substantial market growth for Prevacid IV is not anticipated. The market is mature, and the primary driver for any continued sales is the established clinical utility in specific acute care scenarios.

Key Takeaways

Prevacid IV's market performance is a case study in pharmaceutical patent cliffs and the subsequent impact of generic competition. The product has transitioned from a revenue driver during its patent-protected phase to a mature, lower-margin product. Its current market position is characterized by reduced market share and pricing pressure due to the availability of lower-cost generic alternatives. Future sales are expected to remain stable but at significantly reduced levels, serving a niche in acute care settings.

Frequently Asked Questions

1. When did the primary patent for lansoprazole expire in the U.S.? The primary U.S. patent for lansoprazole expired in November 2005.
2. What are the main indications for Prevacid IV in the U.S.? Prevacid IV is primarily used for the treatment of erosive esophagitis, active duodenal and gastric ulcers, maintenance of healing of erosive esophagitis, and stress ulcer prophylaxis in critically ill patients.
3. Who are the main competitors to Prevacid IV in the U.S. intravenous market? The main competitor is pantoprazole sodium for injection, along with generic versions of lansoprazole for injection.
4. Has the price of Prevacid IV decreased significantly since generic entry? Yes, the price of branded Prevacid IV has decreased significantly due to the introduction of generic alternatives, though it typically remains at a premium compared to generics.
5. What is the expected market growth for Prevacid IV in the next five years? Substantial market growth for Prevacid IV is not anticipated; its market is considered mature with sales likely to remain stable at reduced levels.

Citations

[1] U.S. Patent 4,628,098. (1986). 2-(2-Furanylmethyl)sulfinyl]-1H-benzimidazole derivatives. United States Patent and Trademark Office. [2] U.S. Food and Drug Administration. (n.d.). Orange Book. Retrieved from https://www.fda.gov/drugs/patent-certification-and-compliance-infringement/approved-drug-products-reference-list-orange-book [3] Takeda Pharmaceuticals U.S.A., Inc. (2023). PREVACID® Injection Full Prescribing Information. [4] Multiple market analysis reports and pharmaceutical pricing databases (e.g., IQVIA, Symphony Health Solutions) indicating price erosion post-genericization. Specific reports not publicly cited due to proprietary nature.